Medical products maker Stryker reported double-digit profit growth every quarter this past year, and double digit revenue growth in all-but-one of those quarters. The question is: Can it keep growing at a good clip this year?
On Monday the Relative Strength (RS) Rating for Stryker stock got an upgrade from 70 to 74. The upgraded 74 RS Rating shows that Stryker topped 74% of stocks for price performance over the past year.
Stryker RS Rating Good, Other Ratings Better
Stocks that go on to make the biggest gains often have an 80 or better RS Rating in the early stages of their moves. See if Stryker can continue to rebound and clear that threshold.
Meanwhile, its other ratings shine. Stryker has an 88 EPS Rating and an 89 Composite Rating, putting it in the top 11% of stocks overall. The best growth stocks often have a 90 or higher Composite before launching big runs higher.
It boasts an SMR Rating (sales + profit margins + return on equity) of A on an A-to-E scale.
And its C Accumulation/Distribution Rating show about as many funds are buying its shares as selling. However, a bullish indicator is that the number of funds holding shares of Stryker rose from 3,089 in the June-ended quarter to 3,112 in December.
How To Invest In Stocks In Both Bull And Bear Markets
Stryker is based in Portage, Mich., near Kalamazoo. It makes a wide variety of medical equipment including orthopedic implants, surgical instruments, spinal and emergency treatment gear and other devices.
Watchlist candidate Stryker stock is building a flat base with a 398.20 entry. See if the stock can break out in volume at least 40% higher than normal.
Stryker stock dropped to a 30.82 low at the end of March 2009 as the recession was ending. Monday afternoon Stryker traded near 362, down for the day amid the current market correction.
Analyst Consensus For 2025
Earnings grew 17% last quarter to $2.87 per share, up from 11% in the prior report. Revenue growth also increased, from 9% to 12%, to $5.49 billion. Stryker says on its website it will hold a conference call on Jan. 28 with analysts to discuss its Q4 and full year 2024 earnings results.
Analyst consensus, according to FactSet, is for double-digit EPS growth to continue for at least the next three quarters. Sales are expected to keep growing, but perhaps at a slightly slower pace.
Stryker earns the No. 13 rank among its peers in the Medical-Products industry group. Globus Medical, Boston Scientific and Insulet are among the top five highly rated stocks within the group.
The exclusive Relative Strength Rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Please follow James DeTar on Twitter @JimDeTar
RELATED:
Stocks With Rising Relative Strength Ratings
Get Full Access To IBD Stock Lists And Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
